###### Key messages

What is the key question?
=========================

-   What is the effectiveness of a structured education pulmonary rehabilitation programme delivered at the level of the general practice on the health status of people with moderate chronic obstructive pulmonary disease (COPD)?

What is the bottom line?
========================

-   Participants allocated to a primary care based structured education pulmonary rehabilitation programme had statistically significant higher mean Chronic Respiratory Questionnaire Total, Dyspnoea and Physical scores. However, CIs do not exclude a smaller difference than those prespecified as clinically important.

Why read on?
============

-   This study demonstrates that a primary care based structured education pulmonary rehabilitation programme is feasible and may increase local accessibility to people with moderate and severe COPD.

Introduction {#s1}
============

A key recommendation in the treatment of chronic obstructive pulmonary disease (COPD) is the use of pulmonary rehabilitation programmes (PRPs)[@R1] focusing on self-management techniques. These have been found to improve COPD patients' dyspnoea and health related quality of life.[@R2]--[@R4] Furthermore, programmes adhering to the principles of structured education are more effective in promoting self-management in chronic conditions than unstructured programmes.[@R5] Structured education programmes differ from conventional educational programmes in that they are underpinned by key criteria (online supplementary file 1). However, few PRPs adhere to the key criteria of structured education. Furthermore, PRPs are predominantly hospital based with long waiting lists[@R6] with limited access for general practitioners (GPs) and their patients. There is a lack of research to support the effectiveness of PRPs and in particular the effectiveness of structured education PRPs (SEPRP). We carried out a single-blind, cluster randomised controlled trial to evaluate the effectiveness of a SEPRP, delivered at the level of the general practice, on the health status of people with COPD.

Methods {#s2}
=======

The trial methods have been reported previously.[@R7] GP practices were eligible to participate if they used a computerised medication recording system, employed a practice nurse and had a client population \>2500 people. Participants were identified from the patient\'s medical records using a patient eligibility identification algorithm ([figure 1](#THORAXJNL2012203103F1){ref-type="fig"}). Potential participants were invited for spirometry testing and those with moderate to severe COPD, as defined by Global Initiative for Chronic Lung Disease (GOLD),[@R8] were invited to participate.

![Patient eligibility identification algorithm. Access the article online to view this figure in colour.](thoraxjnl-2012-203103f01){#THORAXJNL2012203103F1}

The primary outcome was the total score of the disease specific quality of life instrument, the Chronic Respiratory Questionnaire (CRQ).[@R9] This instrument consists of 20 items across four domains: dyspnoea (five items), fatigue (four items), emotional function (seven items) and mastery (four items). Higher scores represent less impairment in quality of life domains. Secondary outcomes were the incremental shuttle walk test (ISWT) and the self-efficacy for managing chronic disease 6-Item scale.[@R10] EuroQol EQ-5D[@R11] and utilisation of healthcare services data were also collected which will be reported separately.

We chose a cluster randomised design to minimise the risk that the SEPRP delivered by the practice team to the experimental group might influence the care they provided to control group participants. Group allocation concealment was achieved by giving responsibility for computerised allocation sequence generation and group allocation to a researcher independent of the research team and blinded to baseline outcome data. To minimise time delay and patient attrition, practices were randomised to control or intervention groups in four groups of eligible practices on a 1:1 ratio. Due to the participative nature of the SEPRP, it was not possible to blind either participants or practices to their group allocation. Participants allocated to the intervention received the SEPRP while those allocated to the control group received usual care. The development of SEPRP is described in detail elsewhere[@R12] and the contents of SEPRP are outlined in the online supplementary file 2.

We undertook a descriptive qualitative study interviewing GPs, practice nurses and participants allocated to the control group to describe 'usual care'. This revealed that participants with COPD attended their GP when they felt unwell and were prescribed medications. Most did not receive advice on exercising or breathing techniques and few had any real understanding of COPD.

Research assistants trained in outcome assessment, blinded to group allocation, collected data 12--14 weeks after the programme. The research assistants entering and performing data analyses were blinded to group allocation. We used single data entry with visual verification on a predetermined random sample of records from the data set determined using a continuous sampling plan (CSP-1).[@R13] We reviewed full data entry records for 81 participants (23.1%) consisting of 40 720 items of which 42 were inaccurate for an outgoing accuracy rate of 99.9%.

Sample size calculations {#s2a}
------------------------

We used methods for standard sample size estimates for trials that randomised at the level of the individual and adjusted for clustering by inflating sample size estimates by the design effect of 1+(m* *− 1)ρ (m average cluster size, and ρ estimated intraclass correlation coefficient (ICC)).[@R14] The sample size was based on the mean difference (MD) between intervention and control groups in the total CRQ (primary outcome) for which the minimal clinically important difference (MCID) had been identified in the literature as 0.5[@R15] with an estimated SD of 1.145.[@R16] Using the above values and an ICC of 0.05 based on studies involving older persons in primary care,[@R17] 32 practices each with a minimum of 10 participants were required for power of at least 80% with an α level of 0.05. This calculation allowed for a loss of 20% of participants and of four general practices.

Statistical analysis {#s2b}
--------------------

Statistical analyses are reported according to the CONSORT guidelines.[@R18] We performed an intention to treat analysis using multiple imputation based on chained equations to impute missing data.

We used a linear mixed model with a cluster specific random effect to estimate and test the effect of the intervention for all continuous primary and secondary responses[@R19] separately to account for similarity between the patients within each cluster. We also investigated cluster specific baseline adjustments.[@R20] Responses at baseline were included as a covariate. A comparison of the results between (i) maximal models where all available covariates were included to correct for age, gender, BMI, smoking history and current smoking status, spirometry results and wider medical history and (ii) the most parsimonious set of predictors chosen using variable selection techniques (ie, stepwise selection and best subsets) was performed. No substantial difference in conclusions was found, so the parsimonious model results are presented below. We used Minitab 16 and R (2.10) to conduct the analysis.

Results {#s3}
=======

The flow of practices and individual participants through random assignment, receiving allocated intervention, loss to follow-up and analysed for the primary outcome of Total CRQ is presented in [figure 2](#THORAXJNL2012203103F2){ref-type="fig"}.

![Flow of participants and practices through trial. Access the article online to view this figure in colour.](thoraxjnl-2012-203103f02){#THORAXJNL2012203103F2}

Recruitment of practices and participants took 15 months (February 2009--May 2010). We screened 259 practices for eligibility of which 227 were excluded (142 did not meet the inclusion criteria and 85 declined to participate). Practices that declined participation did not provide specific details on practice characteristics. Reasons given for declining included pressure of work, disinterest, maternity leave and staff sickness. Participating practices were similar in terms of practice size, number of GPs/practice nurses and were representative of national practices identified by Kavanagh *et al*.[@R21] We screened 1146 potential patient participants for eligibility of which 615 were excluded prior to randomisation (564 did not meet spirometry inclusion criteria and 51 were excluded on other medical grounds).

A further 100 eligible participants were excluded prior to randomisation because the practices they were attending had insufficient numbers of participating patients and were therefore excluded. Of the remaining 431 participants, 350 attended for baseline assessment and were subsequently randomised.

We assigned 32 practices with 350 participants randomly to intervention (16 practices, 178 participants) and control (16 practices, 172 participants). [Table 1](#THORAXJNL2012203103TB1){ref-type="table"} shows the characteristics of the cluster and demographic and clinical characteristics of participants at baseline. The ratio of male to female participants was approximately 2:1 and the majority of participants were married or living with their partner, had free medical care eligibility^[i](#fn1){ref-type="fn"}^ and were retired.

###### 

Characteristics of general practices and baseline demographic and clinical characteristics of COPD patients assigned to intervention (structured education pulmonary rehabilitation programme) or continued usual care

  Characteristics                              Intervention group (n=178 participants)   Control group (n=172 participants)
  -------------------------------------------- ----------------------------------------- ------------------------------------
  No. of practices                             16                                        16
  Median (range) of participants per cluster   11 (8--14)                                10 (9--14)
  GP practice (cluster)                                                                  
   Urban                                       32 (18.0)                                 61 (35.5)
   Rural                                       146 (82.0)                                111 (64.5)
   \<5000 patients                             88 (49.4)                                 64 (37.2)
   \>5000 patients                             90 (50.6)                                 108 (62.8)
  Mean (SD) age (years)                        68.8 (10.2)                               68.4 (10.3)
  Gender                                                                                 
   Male (n, %)                                 117 (65.7)                                106 (61.6)
   Female (n, %)                               61 (34.3)                                 66 (38.4)
  Marital status                                                                         
   Married/living with partner                 111 (62.4)                                115 (66.9)
   Separated/divorced                          15 (8.4)                                  10 (5.8)
   Widowed                                     26 (14.6)                                 21 (12.2)
   Single/never married                        26 (14.6)                                 26 (15.1)
   Medical card holder                         141 (79.2)                                152 (88.4)
  Employment status                                                                      
   Paid work: employee                         17 (9.6)                                  12 (7.0)
   Paid work: self-employed                    14 (7.9)                                  8 (4.7)
   Homemaker                                   26 (14.6)                                 19 (11.0)
   Unemployed looking for work                 8 (4.5)                                   8 (4.7)
   Retired                                     92 (51.7)                                 111 (64.5)
   Unable to work disability                   16 (9.0)                                  9 (5.2)
   Other                                       5 (2.8)                                   5 (2.9)
  Spirometry (postbronchodilator)                                                        
   FEV~1~ (% predicted) (mean (SD))            57.6 (14.3)                               59.7 (13.8)
   FEV~1~ (mean (SD))                          1.5 (0.49)                                1.5 (0.52)
   FEV~1~ to FVC % (mean (SD))                 52.9 (11.5)                               55.4 (11.9)
  GOLD 3 severe COPD\* n=97 (27.7%)            56 (31.5%)                                41 (23.8%)
  GOLD 2 moderate COPD\* n=253 (72.3%)         122 (68.5%)                               131 (76.2%)
  Patient history (from medical records)                                                 
   Hypertension or high cholesterol            66 (37.1)                                 76 (44.2)
   Cardiovascular disease                      41 (23.0)                                 62 (36.0)
   Muscoskeletal problems                      66 (37.1)                                 73 (42.4)
   Diabetes                                    22 (12.4)                                 28 (16.3)
   Asthma†                                     38 (22.1)                                 41 (23.0)
   Gastrointestinal disorders                  43 (24.2)                                 46 (26.7)
   CNS disorders                               18 (10.1)                                 21 (12.2)
   Mental health problems                      28 (15.7)                                 27 (15.7)
   Use of inhalers                             155 (87.1)                                158 (91.9)
   Home oxygen                                 6 (3.4)                                   11 (6.4)
   Never smoked                                16 (9.0)                                  27 (15.7)
   Current smoker (n, %)                       70 (39.3)                                 59 (34.3)
   Males currently smoking (n, %)              44 (37.6%)                                33 (31.1%)
   Females currently smoking (n, %)            26 (42.6%)                                26 (39.4%)

Values are numbers (percentages) unless stated otherwise.

\*Classification of COPD based on the GOLD (2006) classification criteria.

†Three participants reversed greater than what was indicated (\>12% and 200 ml increase in FEV~1~) but the results for these three participants were still within the ranges of results for COPD on their postbronchodilator spirometry. None of the other FEV~1~ spirometry results were outside the reversibility limits.

CNS, central nervous system disorders; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; GP, general practitioner.

Coexisting medical disease was common and approximately a third of participants were current smokers ([table 1](#THORAXJNL2012203103TB1){ref-type="table"}).

The median number of participants in each intervention and control cluster was 11 (range 8--14) and 10 (range 9--14), respectively. Due to lack of staff, which was exacerbated by a H1N1 outbreak, one cluster with 10 participants assigned to the intervention withdrew prior to participants receiving the SEPRP. Of the remaining 168 participants, 23 (14%) did not attend any education session, 28 (17%) attended 1--3 sessions, 21 (12%) attended 4--5 sessions and 96 (57%) attended 6--8 sessions. Illness and hospitalisation was the most common reason given for non-attendance (n=62, 37%). Other reasons included working (n=16, 10%), holidays (n=7, 4%), family illness (n=7, 4%) and disinterest (n=14, 8%). In all, 35 of the 178 participants (19.7%) allocated to the intervention and 38 of the 172 allocated to the control groups (22.1%) did not complete the CRQ ([figure 2](#THORAXJNL2012203103F2){ref-type="fig"}). [Table 2](#THORAXJNL2012203103TB2){ref-type="table"} presents data on outcomes prior to the intervention and at 12--14 weeks after completion of the SEPRP. Compared with participants in the control group, those allocated to the intervention had significantly higher CRQ Total (p=0.006), Dyspnoea (p=0.04), Emotional (p=0.06), Physical (p=0.013) and Psychological (p=0.03) baseline scores. Hence, correction for the baseline values was needed to ensure no allocation or covariate bias on the estimated effects.

Participants allocated to the intervention had statistically significant higher mean change total CRQ scores. However, the CI for the total CRQ score difference does not exclude a smaller difference than the one that was prespecified as clinically important. Using methods described by Guyatt *et al*[@R22] we calculated the number needed to treat (NNT) for the Total CRQ as 7.

Participants allocated to the intervention also had statistically significant higher mean CRQ Dyspnoea scores after intervention and CRQ Physical scores. However, as with total CRQ scores, CIs for differences in mean change scores for the CRQ Dyspnoea and CRQ Physical subscales do not exclude smaller differences as prespecified as clinically important. The NNT for CRQ Dyspnoea is 5.5.

There was no statistically significant difference between groups in all other secondary outcomes ([table 2](#THORAXJNL2012203103TB2){ref-type="table"}). Results are consistent when missing values are ignored or when multiple imputation was used, when correcting for all covariates and when a subset of the best predictors are chosen using variable selection. For the CRQ response variables, there was little evidence of any substantial cluster effect.

###### 

Outcomes according to intervention and control group allocation

                                  Baseline       After intervention   Effect estimate                                                    
  ------------------------------- -------------- -------------------- ----------------- ------------- ------ ------------------ -------- ---------
  CRQ                                                                                                                                    
   Total                          19.03 (4.16)   17.8 (4.56)          20.82 (3.88)      19.1 (4.63)   1.11   (0.35 to 1.87)     \<0.01   \<0.1
   Dyspnoea                       3.74 (1.20)    3.45 (1.39)          4.42 (1.36)       3.85 (1.45)   0.49   (0.20 to 0.78)     \<0.01   \<0.001
   Fatigue                        4.33 (1.31)    4.05 (1.48)          4.79 (1.31)       4.33 (1.47)   0.25   (−0.002 to 0.51)   0.07     \<0.001
   Emotional                      5.39 (1.22)    5.01 (1.34)          5.62 (1.19)       5.24 (1.30)   0.19   (−0.02 to 0.40)    0.10     \<0.001
   Mastery                        5.42 (1.31)    5.25 (1.38)          5.94 (1.11)       5.59 (1.30)   0.19   (−0.05 to 0.44)    0.15     0.032
   Physical                       4.09 (1.12)    3.77 (1.23)          4.62 (1.10)       4.12 (1.29)   0.37   (0.14 to 0.60)     \<0.01   \<0.001
   Psychological                  5.41 (1.16)    5.13 (1.26)          5.78 (1.06)       5.41 (1.22)   0.18   (−0.02 to 0.39)    0.10     0.009
   Incremental Shuttle Walk (m)   279 (152)      272 (142)            308 (152)         299 (162)     7.89   (−9.56 to 25.34)   0.39     0.02
   Self-efficacy                  7.24 (1.78)    6.85 (2.02)          7.95 (1.49)       7.36 (1.79)   0.36   (−0.14 to 0.86)    0.18     0.176

Values are means (SD).

\*Baseline and covariate adjusted mean difference (Intervention---Control).

CRQ, Chronic Respiratory Questionnaire; ICC, intraclass correlation coefficient.

We explored intervention effects for participants who had attended all (100%, n=8), 1%--49% (n=2--3) and 50%--99% (n=4--7) of education sessions. Intervention effects were consistent with overall affects for those who had attended all (MD 0.59, 95% CI 0.13 to 1.06) and 50%--99% (MD 0.61, 95% CI 0.21 to 1.01) of sessions but not for those who attended 1%--49% of sessions (MD 0.37, 95% CI −0.30 to 0.97).

There were two minor adverse events; one when a participant experienced shortness of breath undertaking the ISWT at baseline outcome assessment, and the second occurred when another participant on arrival at an intervention session complained of chest pain. Both participants were immediately referred to their respective GPs and both had uneventful recoveries. There were no other adverse events recorded.

Discussion {#s4}
==========

We demonstrate that a 22--24-week complex intervention (SEPRP) targeted at improving the health status of persons with moderate to severe COPD results in a statistically significant improvement of total CRQ scores. However, the CIs for the total CRQ change scores and the CRQ Dyspnoea and CRQ Physical subscale change scores do not exclude a smaller difference than the one that was prespecified as clinically important. The NNT for an additional beneficial outcome in the Total CRQ is 7 and for CRQ Dyspnoea the NNT is 5.5. These NNT values could be attractive to clinicians, people with COPD and funders. Importantly, referring seven patients per year to PRP such as that offered in this study can be expected to yield, on average, additional improvement at 12--14 weeks.

In contrast with most of the trials included in the Cochrane systematic review,[@R3] most participants in our study had moderate COPD (forced expiratory volume in 1 s (FEV~1~) around 55%--60% predicted). This might be an important factor determining the absence of a clinically significant treatment effect.

Although the changes in the ISWT and self-efficacy measures in the intervention demonstrate improvements there was no statistically significant difference between groups. This lack of change in the ISWT appears to be consistent with more recent literature, which queries the responsiveness of ISWT to capture improvements in exercise tolerance following exercise interventions in persons with COPD.[@R23] The lack of change in self-efficacy is unclear, but it may be that receiving a diagnosis of COPD and learning more about the condition as participants progressed through the SEPRP may have inadvertently led to lower scores in self-efficacy, not because behaviour change had not occurred but because participants were more aware of the condition and how it impacted on their lives relative to baseline.

This is one of the largest trials evaluating the effects of PRPs for people with COPD. The Cochrane review of PR versus standard care by Lacasse *et al*[@R3] includes 31 trials of which the largest includes 200 randomised participants[@R24] while the smallest includes 14.[@R25] Furthermore, the majority of PRPs in the Cochrane review were conducted in outpatient departments (n=15), home based (n=9), inpatient (n=3), house bound (n=1) or involved a combination of inpatient and home based (n=1) or outpatient and home based (n=1). Only one programme was delivered in the community.[@R26] This study[@R26] reported statistically significant improvements in exercise and quality of life outcomes for PRP, which included drug therapy compared with drug therapy alone. This was a small cross over trial conducted in eight physiotherapy practices and study participants were patients with asthma (n=43) and COPD (n=23). Waterhouse *et al*[@R27] randomised 240 patients to community or hospital based PRP and found that community based PRP has similar efficacy to hospital based programmes. However, unlike our study there was no usual care arm and the intervention was delivered in both settings by the same hospital physiotherapy team.

Accessibility to PRPs is a well recognised international problem[@R28] and until recently most programmes were hospital based. Exploring the potential effectiveness therefore of PRPs delivered in alternative clinical settings as we have done is crucial.

Many of the hospital based PRPs use expensive equipment and are delivered by respiratory specialists. We used inexpensive equipment and trained practice nurses and physiotherapists with no prior COPD expertise to facilitate a PRP in primary care.

In line with recent recommendations,[@R29] we updated the current Cochrane systematic review by Lacasse *et al*[@R3] on the effectiveness of PR for COPD to include the findings of the PRINCE trial. We did this by including unadjusted changes in mean scores (and SDs) for dyspnoea, fatigue, emotional function and mastery domains of the CRQ in RevMan with the currently included data set available in the Cochrane review. Our findings for fatigue, emotional function and mastery domains are consistent with four, eight and four of the 11 trials included in the meta-analyses[@R3] for these outcomes, respectively. Our finding of a statistically significant improvement in CRQ Dyspnoea is consistent with the summary meta-analysis estimate and with the findings of each of the 11 trials included in the meta-analysis. The reasons for differences between our findings and those of the Cochrane review might be that, in contrast to most of the trials included in the Cochrane review, the majority of patients in our study had moderate COPD (FEV~1~ between 55% and 60% predicted). Therefore, the severity of COPD might be an important factor in determining treatment effect. Further, unlike the trials included in the Cochrane review, we examined the impact of PR 12--14 weeks after the programme. Our results may confirm that in routine practice the effects of PRPs tend to disappear rapidly.[@R30]

The inclusion of PRINCE in the Cochrane review strengthens the findings of the review and increases its power but does not result in changing the direction or statistical significance of CRQ domain outcomes. However, as most trials included in the review[@R3] were hospital or home based, the inclusion of our findings might best be considered in the update of the review by Lacasse *et al*[@R3] (currently underway by some of the authors) and also that subgroup analyses by programme setting (ie, community based vs acute/hospital based) be considered within this review.

Limitations {#s5}
===========

We randomised participants to control and intervention following the collection of baseline data and the demographic data indicated that both groups were well matched. There was no feasible way to blind the intervention group to participants or to those facilitating the programme and our study is open to a risk of performance bias. Nevertheless, outcome assessment was blinded thus minimising risks to detection bias.

Rehabilitation studies usually perform assessment measures immediately after completion of the intervention in addition to longer term outcomes to differentiate between the effect of the intervention and the impact of maintenance. Unfortunately, budgetary constraints only allowed one round of postoutcome data collection after completion of the intervention.

There were 16 different teams (a practice nurse and a physiotherapist from each intervention practice) delivering the SEPRP. Although we provided intensive training, created a detailed programme manual and implemented quality control measures (see online supplementary file 3), it is not known if the intervention was always delivered consistently. However, we felt that this approach ensured that the knowledge gained remained within primary care potentially having a more lasting impact.

We excluded participants with very severe COPD due to concerns for their safety and health risks. Of the 1146 patients screened for eligibility, 350 were randomised. This is not unusual for trials, in which obtaining a homogenous sample is prioritised and in general practice where disease coding may be pragmatic. Indeed, Waterhouse *et al*[@R27] eventually randomised 326 patients from 1041 potentially eligible patients. Further work is also needed to delineate the factors that contribute or hinder the ability of people to maintain improvements over time.

In conclusion, physiotherapists and practice nurses who have no prior COPD expertise can be trained to deliver a SEPRP to people with moderate and severe COPD, thereby increasing local accessibility. However, the CIs for the total CRQ change scores and the CRQ Dyspnoea and CRQ Physical subscale change scores do not exclude a smaller difference than the one that was prespecified as clinically important.
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